ClinicalTrials.gg
Active, not recruitingNCT04309409NivoMelaUpdated May 23, 2024

Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma

A Phase 3 interventional study of Nivolumab in Malignant Melanoma Stage II, sponsored by University Hospital, Essen. Active, not recruiting at 20 sites in Germany. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-05-23.

Sponsored by University Hospital, Essen · Phase 3, Interventional, and Treatment

How we know · 3 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
374
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 142 studies testing nivolumab in Melanoma — 32 open to participants now, 62 under way, 9 of them phase 3. Nivolumab · Melanoma.

Planned enrollment
18th of 142
374 · median 50
Started
2020
with 11 others
Phase 3
19 of 142
2 open now
Primary completion
2027-09
later than 39 of 61 live
Registered
79th of 142
by date

Among the 142 studies testing nivolumab in Melanoma, this one is the 18th largest by planned enrollment, is one of 12 that started in 2020, is one of 19 in phase 3, reaches primary completion later than 39 of the 61 other live ones, and was the 79th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

32 of the 142 studies testing nivolumab in Melanoma are open now, in 12 countries. Recruiting first, the newest first:

27 more — sign in →

By country, each count listing its studies:

All 32 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies testing nivolumab in Melanoma, or all of them as a file.
02

Study summary

Stage II patients with primary surgical treatment of cuMM are often at risk for recurrence of their disease. This risk may be reduced by adjuvant systemic treatment. Due to toxicities of adjuvant therapies the aim is to identify patients at high risk for relapse and to administer adjuvant treatment only to these patients. Thus an optimal balance between insufficient treatment vs. overtreatment has to be found.

To define these patients a prognostic biomarker test will be used in addition to conventional AJCC staging. AJCC staging takes into account several prognostic factors. However, to subdivide stage II melanoma patients into having a low or high risk for relapse further methods are needed.

This clinical trial will evaluate whether adjuvant nivolumab treatment will improve relapse-free survival (RFS) in patients with stage II high-risk melanoma as compared to observation only. The randomized approach of this trial offers the most objective method with the least influence of bias. Since patients with stage II melanoma are usually not receiving adjuvant treatment, no patient will be undertreated in case of randomization into observational arm.

Read the detailed description

The NivoMela trial is a randomized, controlled, prospective, multi-center national phase III trial with biomarker-based risk stratification.

Stage II melanoma patients having undergone surgery of the malignant melanoma will be screened using the MelaGenix GEP score to identify patients at high risk for relapse. It is expected, that 61% of screened patients will belong to this group.

Patients with a risk score of > 0.0 (HR 1.48, 1.11-1.98) corresponding to high risk of relapse will be randomized at a ratio of 2:1 to receive either nivolumab as adjuvant treatment (arm A) or observation only (arm B).

Stratification factors for randomization are:

  1. Tumor stage: IIA versus IIB versus IIC
  2. Gender: Female versus Male
  3. Site of primary tumor: extremities versus trunk versus head \&neck

All screened patients with a risk score of ≤ 0.0 who are not eligible for randomization will be followed for RFS, DMFS and OS for at least 5 years according to German Follow-up guidelines (Arm C).

Various factors that could potentially predict clinical response and incidence of AEs to treatment with nivolumab will be investigated in peripheral blood and tumor specimen taken at baseline. Data from these investigations will be evaluated for associations with clinical efficacy (eg, ORR, PFS, OS) and safety/toxicity (AE). The samples may also be used for exploratory analyses to assess biomarkers associated with melanoma and/or with immunotherapy treatment.

03

Conditions studied

  • Malignant Melanoma Stage II

Browse trials for

Keywords

  • Stage II malignant melanoma
  • patients having undergone surgery
  • IIA melanoma
  • IIB melanoma
  • IIC melanoma
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed diagnosis of stage II (AJCCv8) melanoma arising from a primary cutaneous site after surgery therapy
  2. Sentinel node (SNB) without detection of melanoma deposits
  3. Randomization not later than 12 weeks after SNB procedure
  4. Tumor tissue from primary tumor must be provided for biomarker analyses. In order to be randomized, a subject must be classified by MelaGenix risk analysis.
  5. Men and women at the age of 18 to 80 years
  6. Signed written,
  7. Patients must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study
  8. Minimum of five years excluding their melanoma diagnosis
  9. performance status of 0-1
  10. Screening laboratory values must meet the following criteria and should be obtained within 14 days prior to randomization:

    • White blood cells (WBC) ≥ 2000/μL
    • Neutrophils ≥ 1500/μL
    • ≥ 100 x103/μL
    • ≥ 9.0 g/dL
    • Serum creatinine ≤ 1.5xUL
    • (CrCl) ≥ 40mL/min (using the Cockcroft-Gault formula)
    • / ALT ≤ 3 x
    • Total ≤ 1.5 x ULN (except subjects with Gilbert Syndrome, who may have total bilirubin \< 3.0 mg/dL)
  11. Negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) for women of (WOCBP) within 72 hours prior to registration.

    Women will be considered to be of childbearing potential unless surgically sterilized (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy), or being for at least 24 months or being amenorrheic for > 12 months and follicle-stimulating hormone (FSH) levels ≥ 40 IU/L.

  12. WOCBP and male patients with partners of childbearing potential must agree to always use a highly effective form of according to CTFG during the course of this study and for at least 5 months after last dose of study medication (in Arm A only).

Exclusion criteria

Exclusion Criteria:

  1. History of primary uveal or mucosal melanoma
  2. No access to sufficient tumor tissue of primary tumor
  3. SNB procedure > 12 weeks before randomization
  4. Prior active within the previous 3 years except for locally curable cancers that have been apparently cured, such as: basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the prostate, cervix, or breast. Exception: Participants with a history of non-ulcerated cutaneous/acral primary melanoma \<1 mm in depth with no nodal involvement are allowed in this trial.
  5. Prior or planned therapy with Interferon alpha, CTLA4 or / PD L1 antibodies
  6. Use of any or non-registered product (drug or vaccine) other than the study treatment
  7. Administration of within 4 weeks before start of study therapy
  8. Any therapy given within the past 30 days
  9. Active psychiatric or addictive disorders that may compromise his/her ability to give or to comply with the trial procedures
  10. Active immune deficiencies or significant disease
  11. Serious cardiac, gastrointestinal, hepatic or pulmonary disease which would reduce to less than five years
  12. Serious intercurrent illness, requiring hospitalization
  13. Other serious illnesses, e.g., serious infections requiring antibiotics or bleeding disorders
  14. The patient is known to be positive for (HIV) or other active chronic infections (, ) or has another confirmed or suspected immunosuppressive or immunodeficient condition
  15. Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results.
  16. to the active substance or to any of the
  17. Participation in another clinical study within the 30 days before registration
  18. For female patients: Pregnancy or breast-feeding
  19. For and male patients with partners of childbearing potential: Refusal or inability to use effective means of
  20. Lack of availability for clinical follow-up assessments
  21. Legal incapacity or limited legal capacity
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
374 participants (estimated)

Study arms

  • Experimental
    Nivolumab (Arm A)

    Patients with a risk score of \> 0.0 corresponding to high risk of relapse (randomized): Nivolumab will be applied at a flat dose of 480 mg given as 60-minute iv infusion every 4 weeks for 12 doses over 1 year. Afterwards these patients will receive intense clinical follow up according German Follow up guidelines.

    Drug: Nivolumab

  • No intervention
    Observation, High Risk (Arm B)

    Patients with a risk score of \> 0.0 corresponding to high risk of relapse (randomized): Control group (observation only). These patients will receive intense clinical follow up but no further specific therapy according German Follow up guidelines.

  • No intervention
    Observation, Low Risk (Arm C)

    Patients with a risk score of ≤ 0.0 corresponding to low risk of relapse who are not eligible for randomization: These patients will receive intense clinical follow up but no further specific therapy according German Follow up guidelines. Documentation of clinical outcome of these patients.

Interventions

  • 480 mg nivolumab fixed dose given as 60-minute iv infusion every 4 weeks for 12 doses over 1 year

    Also known as: Opdivo

06

What researchers measure

Primary outcomes

  1. Relapse-Free Survival (RFS) rates

    Determination of efficacy of nivolumab in a biomarker-selected high-risk-enriched stage II melanoma patient population in comparison to control receiving observation only in a 2 (Arm A=nivolumab) : 1 (Arm B=observation) randomization, as measured by Relapse-Free Survival (RFS) rates at 36 and 60 months. RFS is defined as the time from date of registration until documented tumor progression date or date of death of any cause, whichever occurs first in all patients tested with the MelaGenix gene expression profiling (GEP).

    Time frame: 5 years

Secondary outcomes

  1. Distant metastasis-free survival (DMFS) rates

    DMFS rates at 36 and 60 months

    Time frame: 5 years

  2. Melanoma-specific survival (MSS) rates

    MSS rates at 36 and 60 months

    Time frame: 5 years

  3. Overall survival (OS) rates

    OS rates at 36 and 60 months

    Time frame: 5 years

  4. Adverse events ≥ Grade 3 according to CTCAE Version 5.0 criteria (Safety / Toxicity)

    All adverse events ≥ Grade 3 according to CTCAE Version 5.0 criteria, that are definitely, probably, or possibly related to the administration of the investigational agent

    Time frame: Arm A: Until 100 days after discontinuation of dosing of the investigational product; Arm B: Until 1 year after patient´s written consent

  5. Clinical utility/decision impact of the MelaGenix Gene Expression Profiling (GEP) Score in stratifying patients for adjuvant therapy

    Patients with a risk score of \> 0.0 (HR 1.48, 1.11-1.98) will be classified as high risk for relapse. It is expected, that 61% of screened patients will belong to this group. Patients with a risk score of score of ≤ 0.0 will be classified as low risk for relapse.

    Time frame: 5 years

Other outcomes

  1. Treatment-free interval (TFI)

    Treatment-free interval (TFI) defined as the time from registration/randomization to the start of subsequent systemic therapy or the last known date alive (for those who never received subsequent cancer therapy).

    Time frame: 5 years

  2. Tumor mutational burden (TMB)

    Time frame: 5 years

07

Study locations

20 sites
  • Universitätsklinikum Würzburg - Klinik für Dermatologie, Venerologie und Allergologie
    Würzburg, Bayern 97080, Germany
  • Universitätsmedizin Rostock -Klinik und Poliklinik für Dermatologie und Venerologie
    Rostock, Mecklenburg-Vorpommern 18057, Germany
  • Universitätsklinikum Augsburg, Campus Süd
    Augsburg, 86179, Germany
  • St. Josef-Hospital - Dermatologische Studienambulanz
    Bochum, 44791, Germany
  • Klinikum Dortmund gGmbH - Dermatologie
    Dortmund, 44137, Germany
  • Universitätsklinik Carl Gustav Carus der Technischen Universität Dresden - Klinik und Poliklinik für Dermatologie
    Dresden, 01307, Germany
  • HELIOS Klinikum Erfurt
    Erfurt, 99089, Germany
  • University Hospital Essen, Department of Dermatology, Skin Cancer Center
    Essen, 45122, Germany
  • Universitätsklinikum Freiburg - Klinik für Dermatologie und Venerologie
    Freiburg, 79106, Germany
  • Universitätsklinikum Gießen und Marburg GmbH - Klinik für Dermatologie und Allergologie
    Gießen, 35392, Germany
  • Universitätsklinikum Hamburg-Eppendorf - Hauttumorzentrum
    Hamburg, 20246, Germany
  • Universitätsklinikum Schleswig-Holstein, Campus Kiel - Dermatologie
    Kiel, 24105, Germany
  • Universitätsklinikum Leipzig - Klinik u. Poliklinik f. Dermatologie, Venerologie u. Allergologie
    Leipzig, 04103, Germany
  • Universitätsklinikum Mannheim - Klinik f. Dermatologie, Venerologie u. Allergologie
    Mannheim, 68167, Germany
  • Klinikum der Universität München - Klinik und Poliklinik für Dermatologie und Allergologie
    München, 80337, Germany
  • Universitätsklinikum Münster - Zentrale Studienkoordination für innovative Dermatologie (ZID)
    Münster, 48149, Germany
  • Fachklinik Hornheide - Internistische Onkologie
    Münster, 48157, Germany
  • Klinikum Nürnberg Nord - Hautklinik
    Nürnberg, 90419, Germany
  • Harzklinikum Dorothea Christiane Erxleben - Klinik für Dermatologie & Allergologie
    Quedlinburg, 06484, Germany
  • Universitätsklinikum Tübingen - Dermatoonkologie
    Tübingen, 72076, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2020 (actual). Primary completion is estimated for Sep 2027, 86 months after the start.

Of 95 phase 3 interventional studies under Melanoma, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 94. This study's planned 86 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2020
First posted
Mar 16, 2020
StartActual
Jul 1, 2020
Primary completionEst.
Sep 2027
CompletionEst.
Jan 2028
Last update
May 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04309409
Responsible party
Prof. Dr. med. Dirk Schadendorf (Director of the Department of Dermatology and the West German Tumour Centre at the University Hospital, University Hospital, Essen) — Principal investigator
First posted
Mar 16, 2020
Start date
Jul 1, 2020
Primary completion
Sep 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
May 23, 2024

Study contacts

Dirk Schadendorf, Prof. Dr.
principal investigator · University Hospital, Essen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion